UNLABELLED: Vitamin D deficiency is associated with increased fracture risk. The observational study aimed to investigate vitamin D status and supplementation in ambulatory patients. Only 20% of patients had optimal serum 25-hydroxyvitamin D [25(OH)D] levels. Commonly recommended dosages were insufficient to achieve clinically relevant increase of 25(OH)D levels. Higher dosages were safe and effective under clinical practice conditions. INTRODUCTION: Vitamin D deficiency is associated with adverse health outcome. The study aimed to investigate vitamin D status and supplementation in ambulatory patients. METHODS: Nine hundred seventy-five women and 188 men were evaluated for bone status from January 2008 to August 2008 within an observational study; 104 patients (n = 70 osteoporosis) received follow-up after 3 months. Dosage of vitamin D supplementation was documented and serum 25(OH)D and parathyroid hormone (PTH) determined. RESULTS: In all patients (age, 60.4 ± 14.1 years), distribution of 25(OH)D was 56.3 ± 22.3 nmol/L (normal range, 52-182 nmol/L) and PTH 53.8 ± 67.5 ng/L (normal range, 11-43 ng/L). The proportion of patients with 25(OH)D < 25, 25 to <50, 50 to <75, ≥75 nmol/L was 7.5%, 33.3%, 38.9% and 20.2% in the total group and 20.1%, 38.5%, 30.8%, 10.6% at baseline in the follow-up group, respectively. After 3 months, 3.9% had still 25(OH)D < 25 nmol/L; only 12.5% achieved 25(OH)D ≥ 75 nmol/L. In osteoporosis patients, 25(OH)D increased more in those taking ≥1,500 (median, 3,000) IU vitamin D per day (33.1 ± 14.7 nmol/L) compared with ≤1,000 (median, 800) IU/day (10.6 ± 20.0 nmol/L) (p < 0.0008). PTH decreased more in patients taking ≥1,500 IU/day (-13.2 ± 15.2 ng/L) compared with ≤1,000 IU/day (-7.6 ± 19.2 ng/L; p = 0.29). 25(OH)D was negatively correlated to PTH (r = -0.49, p < 0.0001). An increase of 25(OH)D ≥ 75 nmol/L resulted in normalised PTH. CONCLUSION: Supplementation with higher vitamin D dosages (2,000-3,000 IU/day) is required to achieve a relevant increase of 25(OH)D and normalisation of PTH.
UNLABELLED: Vitamin D deficiency is associated with increased fracture risk. The observational study aimed to investigate vitamin D status and supplementation in ambulatory patients. Only 20% of patients had optimal serum 25-hydroxyvitamin D [25(OH)D] levels. Commonly recommended dosages were insufficient to achieve clinically relevant increase of 25(OH)D levels. Higher dosages were safe and effective under clinical practice conditions. INTRODUCTION:Vitamin D deficiency is associated with adverse health outcome. The study aimed to investigate vitamin D status and supplementation in ambulatory patients. METHODS: Nine hundred seventy-five women and 188 men were evaluated for bone status from January 2008 to August 2008 within an observational study; 104 patients (n = 70 osteoporosis) received follow-up after 3 months. Dosage of vitamin D supplementation was documented and serum 25(OH)D and parathyroid hormone (PTH) determined. RESULTS: In all patients (age, 60.4 ± 14.1 years), distribution of 25(OH)D was 56.3 ± 22.3 nmol/L (normal range, 52-182 nmol/L) and PTH 53.8 ± 67.5 ng/L (normal range, 11-43 ng/L). The proportion of patients with 25(OH)D < 25, 25 to <50, 50 to <75, ≥75 nmol/L was 7.5%, 33.3%, 38.9% and 20.2% in the total group and 20.1%, 38.5%, 30.8%, 10.6% at baseline in the follow-up group, respectively. After 3 months, 3.9% had still 25(OH)D < 25 nmol/L; only 12.5% achieved 25(OH)D ≥ 75 nmol/L. In osteoporosispatients, 25(OH)D increased more in those taking ≥1,500 (median, 3,000) IU vitamin D per day (33.1 ± 14.7 nmol/L) compared with ≤1,000 (median, 800) IU/day (10.6 ± 20.0 nmol/L) (p < 0.0008). PTH decreased more in patients taking ≥1,500 IU/day (-13.2 ± 15.2 ng/L) compared with ≤1,000 IU/day (-7.6 ± 19.2 ng/L; p = 0.29). 25(OH)D was negatively correlated to PTH (r = -0.49, p < 0.0001). An increase of 25(OH)D ≥ 75 nmol/L resulted in normalised PTH. CONCLUSION: Supplementation with higher vitamin D dosages (2,000-3,000 IU/day) is required to achieve a relevant increase of 25(OH)D and normalisation of PTH.
Authors: A M Grant; A Avenell; M K Campbell; A M McDonald; G S MacLennan; G C McPherson; F H Anderson; C Cooper; R M Francis; C Donaldson; W J Gillespie; C M Robinson; D J Torgerson; W A Wallace Journal: Lancet Date: 2005 May 7-13 Impact factor: 79.321
Authors: Andrew W Roddam; Rachel Neale; Paul Appleby; Naomi E Allen; Sarah Tipper; Timothy J Key Journal: Am J Epidemiol Date: 2007-08-22 Impact factor: 4.897
Authors: Natalia O Kuchuk; Natasja M van Schoor; Saskia M Pluijm; Arkadi Chines; Paul Lips Journal: J Bone Miner Res Date: 2009-04 Impact factor: 6.741
Authors: J A Kanis; O Johnell; B Gullberg; E Allander; G Dilşen; C Gennari; A A Lopes Vaz; G P Lyritis; G Mazzuoli; L Miravet Journal: BMJ Date: 1992-11-07
Authors: Deborah M Mitchell; Kristin Ruppert; Nisha Udupa; Fatima Bassir; Karin Darakananda; Daniel H Solomon; Yinjuan Lian; Jane A Cauley; Arun S Karlamangla; Gail A Greendale; Joel S Finkelstein; Sherri-Ann M Burnett-Bowie Journal: Clin Endocrinol (Oxf) Date: 2019-04-24 Impact factor: 3.478
Authors: S Gallo; T Hazell; C A Vanstone; S Agellon; G Jones; M L'Abbé; C Rodd; H A Weiler Journal: Osteoporos Int Date: 2016-03-11 Impact factor: 4.507
Authors: Joop P W van den Bergh; Sandrine P G Bours; Tineke A C M van Geel; Piet P Geusens Journal: Curr Osteoporos Rep Date: 2011-03 Impact factor: 5.096
Authors: Chae Jin Lee; Sung Soo Kim; Won Yoon Suh; Jong Sung Kim; Jin Gyu Jung; Seok Joon Yoon; Yu Ri Seo; Hyeon Jeong Yang Journal: J Bone Metab Date: 2019-08-31